Autism 2 Flashcards
What is autism?
Autism is a neurodevelopmental disorder resulting from impairment of growth and development of the cerebrum
When was autism first identified as a condition?
Leo Kanner in 1943 studied 11 children diagnosed with schizophrenia with the same key symptoms. These were aloneness, bizarre repetitive routines, muteness and abnormal speech which he termed the children autistic.
How is the diagnosis of autism made?
Diagnostic and Statistical manual of Mental Disorders- V (DSM-V) characterises the disorder with two criteria; the patient must exhibit deficits in social communication & interaction and a restricted & repetitive behaviour.
Epidemiology of Autism
1 in every 100 people in the UK has ASD (NHS, 2016). There has been a 600% increase in the prevalence of autism in the last 20 years and at least 25% can be attributed to the change in diagnosis criteria set.
Cost of Autism and effect on work
Huge cost and only 16% of autistic adults in the UK are in full-time paid employment, and only 32% are in some kind of paid work (National Autistic Society, 2016).
Name the three genetic diseases associated with autism risk
Tuberous Sclerosis Complex
Fragile X syndrome
16p11.2 deletion syndrome
What is TSC and how common is it?
Tuberous Sclerosis complex is an autosomal dominant disease affecting 1 in 6,000 people.
What did Curatolo et al., 2015 state about TSC?
What are the symptoms and other signs seen in TSC?
It is caused by mutations in either the TSC1 gene on c9 or the TSC2 gene on c16 which encode for hamartin and tuberin respectively.
Involved in the mammalian target or rapamycin (mTOR) signalling pathway as tumour suppressors, mutation of these genes lead to hyperactivation of the mTOR pathway.
The symptoms are caused by this hyperactivity which causes abnormal cell growth, proliferation and tumorigenesis.
In the CNS, cortical tubers grow which displace neural tissues. Other symptoms include adenoma sebaceum and in more than 80% of cases epilepsy begins in the first 3 years of life
How common is autism in TSC? Who stated this and what did it show in development?
Spurling et al. (2014)
A longitudinal cohort study studied infants up to 3 years of age with TSC. Twenty-two of 40 children (55%) with TSC met criteria for ASD.
At 6 months, TSC group showing delays in NVIQ (both FM and VR domains). By age 9 months, infants with TSC exhibited delays in all developmental domains.
Impaired visual tracking, disengagement of attention, and anticipatory responses.
Significant decline in Non Verbal IQ between 12 and 36 months while the non-ASD group showed gains in both full Developmental Quotient and Visual IQ between 12 and 36 months
It was speculated that early visual perception impairment leads to an increase risk decreased social function.
A larger sample size in the first year will enable earlier prediction of ASD however this study does show domain specific decline which could lead to better intervention put in place.
What animal models have been used in TSC and autism?
Rat Model
Eker rats carry a spontaneously occurring germline inactivation of rat orthologue of TSC2
Walterait et al. (2011)
Studied both TSC genotype and developmental epilepsy on social behaviours in TSC2+/- (Eker) and WT rats between 3-6 months.
TSC+/- rats displayed autistic-like deficits such as reduced novel object, environmental and social exploration behaviours in Eker (TSC+/-) rats compared to WT rats
Increased social evade and reduced contact time levels in Eker and WT rats induced with status epilepticus.
Only measured social interaction, one part of diagnostic domain of ASD.
In literature elsewhere, such as in Curatolo et al. (2008), it is known that intellectual deficit in TSC is associated with prolonged seizures and a limitation in this current study regarding the discrepancy is that the kainic acid induced epilepsy may not have been sufficient in duration or intensity, P7-14 is later in development than seizures during the first year of life. This would be an important area to modify in future studies.
What treatment have been used in TSC?
mTOR Inhibitor Treatment
The first mTOR inhibitor was rapamycin which binds to cytosolic protein which inhibits the pathway by direct competition.
Schneider et al. (2016)
Investigated the effects of Everolimus, a second generation mTOR inhibitor, using Walterait et al. (2011) study methods.
Everolimus was shown to reverse the autistic phenotype in social behaviour deficit as measured by social exploration and recognition memory Eker rats.
The limitation to this study is that no control data was taken for either drug induced epilepsy WT rats and Eker rats naïve for induced seizures which would allow more conclusions to be drawn about mTOR inhibitor treatment.
No mechanistic data was taken on the Everolimus treatment and reassessment of social behaviour after washout of Everolimus would identify duration of effect. This is a potential area of further study currently being researched to understand the efficacy of the drug relating with autism.
What is 16p11.2 Deletion Syndrome?
What is the mutation frequenct and how common is it associated with autism?
16p11.2 deletion syndrome is due to de novo recurrent microdeletions which span 500kb
Kumar et al., 2008
A combined frequency of 0.6% of ASD patients, representing the most common recurrent genomic disorder associated with autism. De novo CNVs in patients with autism but not in several of their affected sibs suggests 16p11.2 microdeletion may represent a susceptibility variant
What are the molecular and phenotypic characteristics in 16p11.2 deletion syndrome?
Patients with 16p11.2 mutations showed significant speech and cognitive impairment whilst the deletion group had statistically significant macrocephaly compared to control groups with a broad forehead, flat midface indicative of the disease.
Autism was seen in 20% of deletion cases indicating a clear genetic basis for ASD
What animal models are available for studying 16p11.2 deletion syndrome?
Zebrafish and Mice model
What zebrafish models have been used and why?
What have they shown in 16p11.2 syndrome?
Golzio et al. (2012)
Studied the expression KCTD13 gene in the 16p11.2 deletion syndrome.
A splice blocking morpholino, short antisense oligonucleotides, against KCTD13 reduced expression in the zebrafish and significantly increased macrocephaly due to impaired regulation of early neurogenesis.
Importantly, measurement of the somitic trunk length of scored embryos showed no differences in length, indicating that the head size differences are unlikely to be driven by gross developmental delay.
The data used does not exclude any other loci important or whether all phenotypes are driven by KCTD13.
These findings are associated with human phenotype of both 16p11.2 deletion syndrome and autism which provides valuable insight into the genetic basis of the disease.